Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors

[1]  Nigel H. Greig,et al.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat , 2008, Cancer Chemotherapy and Pharmacology.

[2]  K. Audus,et al.  Evaluation of the Role of P-Glycoprotein in Ivermectin Uptake by Primary Cultures of Bovine Brain Microvessel Endothelial Cells , 1998, Neurochemical Research.

[3]  K. Walter,et al.  Cytotoxicity of taxol in vitro against human and rat malignant brain tumors , 2004, Cancer Chemotherapy and Pharmacology.

[4]  Armin Buschauer,et al.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.

[5]  T. Siegal,et al.  Strategies for Increasing Drug Delivery to the Brain , 2002, Clinical pharmacokinetics.

[6]  Eve M. Taylor,et al.  The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders , 2002, Clinical pharmacokinetics.

[7]  M. Michaelis,et al.  Amyloid peptide toxicity and microtubule-stabilizing drugs , 2002, Journal of Molecular Neuroscience.

[8]  W. Pardridge.  Targeting neurotherapeutic agents through the blood-brain barrier. , 2002, Archives of neurology.

[9]  E. Edelman,et al.  Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. , 2001, Journal of pharmaceutical sciences.

[10]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[11]  M. Michaelis,et al.  Protection Against β‐Amyloid Toxicity in Primary Neurons by Paclitaxel (Taxol) , 1998 .

[12]  J. Cadet,et al.  Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice , 1997, Brain Research.

[13]  I. Ojima,et al.  Synthesis of novel 3'-trifluoromethyl taxoids through effective kinetic resolution of racemic 4-CF3-beta-lactams with baccatins. , 1997, Chirality.

[14]  I. Pastan,et al.  P-glycoprotein and multidrug resistance. , 1996, Current opinion in genetics & development.

[15]  P. Vrignaud,et al.  Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. , 1996, Journal of medicinal chemistry.

[16]  J. Desnottes.  New targets and strategies for the development of antibacterial agents. , 1996, Trends in biotechnology.

[17]  K. Audus,et al.  Brain microvessel endothelial cell culture systems. , 1996, Pharmaceutical biotechnology.

[18]  Q. Smith.  Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. , 1996, Pharmaceutical biotechnology.

[19]  N. Savaraj,et al.  Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. , 1995, Cancer research.

[20]  T. Tsuruo,et al.  P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. , 1992, Life sciences.

[21]  M. Kaczorowska,et al.  [P glycoprotein and multidrug resistance]. , 1991, Patologia polska.

[22]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R T Borchardt,et al.  Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood‐Brain Barrier a , 1987, Annals of the New York Academy of Sciences.